Hyperactivated tumor survival pathways cannot be suppressed without coupling targeted inhibitors with companion diagnostics.
Because specific genomic alterations like PTEN deficiency drive rapid drug resistance and aggressive disease, regulatory approvals for next-generation inhibitors require mandatory matching companion diagnostics.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Gedatolisib's commercial success relies heavily on expanding routine biomarker companion diagnostics to identify the PIK3CA wild-type patients who benefit.
The approval of capivasertib for PTEN-deficient prostate cancer was paired with a mandatory companion diagnostic to identify eligible patients.
The regulatory clearance of Truqap is contingent upon the concurrent endorsement of a test to monitor target-specific PTEN loss.
The FDA approved a new targeted prostate cancer inhibitor strictly in combination with a companion diagnostic designed to verify target PTEN deficiency.